CD22 and acute lymphoblastic leukemia: Inotuzumab ozogamicin is a humanized monoclonal antibody against CD22 antigen conjugated to a cytotoxic derivative of calicheamicin, approved in several countries—including in the USA, EU, and Japan—as monotherapy for the treatment of adults with relapsed/refractory B-ALL.